Subtopic Deep Dive
HER2-Targeted Therapies in Breast Cancer
Research Guide
What is HER2-Targeted Therapies in Breast Cancer?
HER2-targeted therapies use monoclonal antibodies like trastuzumab and tyrosine kinase inhibitors to treat HER2-positive breast cancer by blocking HER2 signaling.
Trastuzumab combined with adjuvant chemotherapy improves disease-free survival in operable HER2-positive breast cancer (Romond et al., 2005, 5323 citations). Adjuvant trastuzumab for 1 year significantly enhances disease-free and overall survival (Slamon et al., 2011, 2733 citations). These therapies target the 15-20% of breast cancers overexpressing HER2.
Why It Matters
HER2-targeted therapies with paclitaxel after doxorubicin and cyclophosphamide reduce recurrence in surgically resected HER2-positive cases (Romond et al., 2005). One-year adjuvant trastuzumab favors nonanthracycline TCH regimens over AC-T plus trastuzumab due to better risk-benefit ratios (Slamon et al., 2011). ESMO guidelines integrate these into diagnosis and treatment protocols for primary breast cancer (Aebi et al., 2010).
Key Research Challenges
Resistance to Trastuzumab
HER2-positive tumors develop resistance to trastuzumab despite initial responses. Romond et al. (2005) showed benefits in adjuvant settings, but long-term data reveal recurrence patterns. Slamon et al. (2011) noted sustained efficacy challenges in diverse patient cohorts.
Optimal Combination Regimens
Combining trastuzumab with chemotherapy like TCH versus AC-T requires balancing efficacy and cardiotoxicity. Slamon et al. (2011) reported TCH superiority in risk-benefit. Identifying best partners remains critical for operable cases (Romond et al., 2005).
Patient Selection via IHC
Accurate HER2 detection via immunohistochemistry guides therapy eligibility. Hammond et al. (2010) provided ASCO/CAP guidelines for ER/PgR testing, extendable to HER2. Variability in testing impacts treatment outcomes.
Essential Papers
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Edward H. Romond, Edith A. Perez, John Bryant et al. · 2005 · New England Journal of Medicine · 5.3K citations
Trastuzumab combined with paclitaxel after doxorubicin and cyclophosphamide improves outcomes among women with surgically removed HER2-positive breast cancer. (ClinicalTrials.gov numbers, NCT000040...
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent, Maureen Trudeau, Kathleen I. Pritchard et al. · 2007 · Clinical Cancer Research · 5.0K citations
Abstract Purpose: To compare the clinical features, natural history, and outcomes for women with “triple-negative” breast cancer with women with other types of breast cancer. Experimental Design: W...
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett et al. · 2010 · Journal of Clinical Oncology · 4.2K citations
Purpose To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptor...
Breast cancer statistics, 2019
Carol DeSantis, Jiemin Ma, Mia M. Gaudet et al. · 2019 · CA A Cancer Journal for Clinicians · 3.2K citations
Abstract This article is the American Cancer Society’s biennial update on female breast cancer statistics in the United States, including data on incidence, mortality, survival, and screening. Over...
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Stefan Aebi, T. Davidson, Günther Gruber et al. · 2010 · Annals of Oncology · 2.9K citations
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Cornelia Liedtke, Chafika Mazouni, Kenneth R. Hess et al. · 2008 · Journal of Clinical Oncology · 2.8K citations
Purpose Triple-negative breast cancer (TNBC) is defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2) expression. In this s...
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis J. Slamon, W. Eiermann, Nicholas J. Robert et al. · 2011 · New England Journal of Medicine · 2.7K citations
The addition of 1 year of adjuvant trastuzumab significantly improved disease-free and overall survival among women with HER2-positive breast cancer. The risk-benefit ratio favored the nonanthracyc...
Reading Guide
Foundational Papers
Read Romond et al. (2005) first for core trastuzumab adjuvant evidence (5323 citations, NCT00004067). Follow with Slamon et al. (2011) for regimen comparisons.
Recent Advances
Study Sparano et al. (2018) for gene assay-guided decisions in HER2-negative contexts; Yin et al. (2020) for molecular subtyping advances applicable to HER2.
Core Methods
Trastuzumab with doxorubicin/cyclophosphamide then paclitaxel (Romond et al., 2005). IHC guidelines for receptor testing (Hammond et al., 2010). TCH nonanthracycline regimens (Slamon et al., 2011).
How PapersFlow Helps You Research HER2-Targeted Therapies in Breast Cancer
Discover & Search
Research Agent uses searchPapers and citationGraph to map trastuzumab trials from Romond et al. (2005, 5323 citations), revealing Slamon et al. (2011) as a key follow-up. exaSearch finds recent HER2 combination studies; findSimilarPapers expands to lapatinib inhibitors.
Analyze & Verify
Analysis Agent applies readPaperContent to extract survival data from Romond et al. (2005), then runPythonAnalysis with pandas to compute hazard ratios across trials. verifyResponse (CoVe) and GRADE grading verify claims like 1-year trastuzumab efficacy (Slamon et al., 2011) against statistical benchmarks.
Synthesize & Write
Synthesis Agent detects gaps in resistance mechanisms post-trastuzumab; Writing Agent uses latexEditText, latexSyncCitations for Romond et al. (2005), and latexCompile to generate review manuscripts. exportMermaid visualizes therapy outcome flowcharts.
Use Cases
"Extract survival statistics from HER2 adjuvant trials and plot Kaplan-Meier curves"
Research Agent → searchPapers('trastuzumab adjuvant') → Analysis Agent → readPaperContent(Romond 2005) → runPythonAnalysis(pandas/matplotlib sandbox) → Kaplan-Meier plots and CSV export.
"Write LaTeX review on trastuzumab combinations citing Romond and Slamon"
Synthesis Agent → gap detection → Writing Agent → latexEditText(draft) → latexSyncCitations(Romond 2005, Slamon 2011) → latexCompile → PDF with synchronized bibliography.
"Find GitHub repos analyzing HER2 trial data from recent papers"
Research Agent → paperExtractUrls(Slamon 2011) → paperFindGithubRepo → Code Discovery → githubRepoInspect → Verified analysis scripts for recurrence modeling.
Automated Workflows
Deep Research workflow scans 50+ HER2 papers via citationGraph from Romond et al. (2005), producing structured reports on adjuvant outcomes. DeepScan applies 7-step CoVe to verify Slamon et al. (2011) survival claims with GRADE scoring. Theorizer generates hypotheses on lapatinib-trastuzumab synergies from trial abstracts.
Frequently Asked Questions
What defines HER2-targeted therapies?
Therapies target HER2 overexpression using trastuzumab monoclonal antibodies combined with chemotherapy like paclitaxel (Romond et al., 2005).
What are key methods in HER2 therapies?
Adjuvant trastuzumab for 1 year with TCH regimen improves survival over AC-T (Slamon et al., 2011). Neoadjuvant combinations assess response via pathological complete response.
What are foundational papers?
Romond et al. (2005, 5323 citations) established trastuzumab plus adjuvant chemotherapy benefits. Slamon et al. (2011, 2733 citations) confirmed 1-year adjuvant efficacy.
What open problems exist?
Resistance mechanisms post-trastuzumab persist; optimal IHC for HER2 selection needs refinement (Hammond et al., 2010). Combination regimens balancing toxicity remain unresolved.
Research Breast Cancer Treatment Studies with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching HER2-Targeted Therapies in Breast Cancer with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
Part of the Breast Cancer Treatment Studies Research Guide